Drug intelligence / Profile preview

NRP2-Mo83

Development stage
Preclinical
Lead developer
University Hospital of Bonn
Modality
Recombinant Proteins and Enzymes
01

Overview

NRP2-Mo83 is a novel, soluble splice isoform of the non-tyrosine kinase receptor Neuropilin-2 (NRP2). Identified in high-expressing tumor cell lines and human serum, this isoform is characterized as a monomeric secreted protein, distinguishing it from the dimeric soluble isoform s9NRP2. Recombinant NRP2-Mo83 exhibits significant antiangiogenic and antitumorigenic properties, demonstrating dose-dependent inhibition of tumor cell growth in bladder carcinoma and inhibition of human endothelial cell (HUVEC) proliferation. The protein undergoes extensive post-translational modifications, including N- and O-glycosylation and polysialation, and its structure is stabilized by calcium ions. NRP2-Mo83 appears to be downregulated during bladder tumorigenesis, suggesting a potential role as an endogenous tumor suppressor and a candidate for therapeutic development in oncology.

Other names
soluble Neuropilin-2 isoform Mo83
02

Targets

SEMA3F (Semaphorin-3F)VEGFD (Vascular endothelial growth factor D)VEGFC (VEGF-C)

Beyond the preview

Go deeper on NRP2-Mo83.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on NRP2-Mo83.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call